AEterna Zentaris (AEZS) Partner, Keryx (KERX), Presented Updated Phase 2 Data on Perifosine (KRX-0401) for the Treatment of Advanced Metastatic Renal Cell Carcinoma
Tweet Send to a Friend
AEterna Zentaris (NASDAQ: AEZS) announced that Keryx Biopharmaceuticals (Nasdaq: KERX), its partner and licensee for perifosine in the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
